Adrenocortical Carcinoma - Improving Patient Care by Establishing New Structures[1]

Abstract

Background: Adrenocortical carcinoma (ACC) is a rare and highly malignant tumour with a poor prognosis. Patients present with signs of steroid hormone excess (e.g., Cushing's syndrome) or symptoms due to an abdominal mass. Diagnosis: In case of an adrenal mass, hormonal workup before surgery is required for differential diagnosis, perioperative management, and for follow-up. The imaging of choice is CT or MRI with MRI being of additional use when invasion of big vessels is suspected. Apart from that, the use of 18-FDG‐PET is becoming increasingly established. Treatment: Surgical resection is the therapeutic option of choice in stages 1 - 3. In stage 4, the adrenolytic compound mitotane is part of the first-line treatment, but often needs to be combined with cytotoxic chemotherapy. Most patients will eventually have a recurrence, so adjuvant treatment (mitotane/tumour bed radiation) has to be considered in high risk patients, even if randomized controlled trials on adjuvant treatment are still lacking. Structural Progress: Several national and European structures have recently been established in order to increase our knowledge of ACC, improve therapeutic options and diagnostic procedures, and promote research. GANIMED, as a Germany-wide network of experts on adrenal diseases, has been founded allowing for improved gathering of data and joint studies. ENSAT (European Network for the Study of Adrenal Tumours) has been brought to life, aiming at European standards for therapy, diagnosis and tumour banking. Since 2003, patients can be enrolled in the German ACC Registry. France and Italy have also developed a central registry to collect nationwide data from patients with ACC. For the first time, patients with metastatic/unresectable ACC can participate in a prospective controlled randomized trial comparing two different cytotoxic chemotherapy regimes (FIRM‐ACT).

Key words

Adrenocortical carcinoma - ACC - Registry - ENSAT - FIRM‐ACT

1 This work was supported by the Deutsche Krebshilfe (grant # 106080) to B. A. and the European Union (grant # MOIF-7394) to M. F.

References

• 1 Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma.  Clin Endocrinol. 2004;  60 273-287
• 2 Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross D J, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L. Etoposide, doxorubicine and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma. A large prospective phase II trial.  Endocrine Related Cancer. 2005;  12 657-666
• 3 Dackiw A P, Lee J E, Gagel R F, Evans D B. Adrenal cortical carcinoma.  World J Surg. 2001;  25 914-926
• 4 DeLellis R A, Lloyd R V, Heitz P U, Eng (eds) C. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Edited. Lyon; IARC Press 2004: 136
• 5 Fassnacht M, Kenn W, Allolio B. Adrenal tumors: how to establish malignancy?.  J Endocrinol Invest. 2004;  27 387-399
• 6 Giordano T J, Thomas D G, Kuick R, Lizyness M, Misek D E, Smith A L, Sanders D, Aljundi R T, Gauger P G, Thompson N W, Taylor J M, Hanash S M. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.  Am J Pathol. 2003;  162 521-531
• 7 Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment.  Curr Opin Investig Drugs. 2005;  6 386-394
• 8 Kann P H, Wirkus B, Behr T, Klose K J, Meyer S. Endosonographic imaging of benign and malignant pheochromocytomas.  J Clin Endocrinol Metab. 2004;  89 1694-1697
• 9 Khan T S, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K, Eriksson B. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.  Ann Oncol. 2000;  11 1281-1287
• 10 Lee A S, Galea C, DiGiammarino E L, Jun B, Murti G, Ribeiro R C, Zambetti G, Schultz C P, Kriwacki R W. Reversible amyloid formation by the p 53 tetramerization domain and a cancer-associated mutant.  J Mol Biol. 2003;  327 699-709
• 11 Lee J E, Berger D H, el-Naggar A K, Hickey R C, Vassilopoulou-Sellin R, Gagel R F, Burgess M A, Evans D B. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma.  Surgery. 1995;  118 1090-1098
• 12 Luton J P, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat M H, Louvel A, Chapuis Y, Blondeau P, Bonnin A, Bricaire H. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.  N Engl J Med. 1990;  322 1195-1201
• 13 MacFarlane D A. Cancer of the adrenal cortiex: the natural history, prognosis and treatment in the study of fifty cases.  Ann R Coll Surg Engl. 1958;  109 613-618
• 14 Malkin D, Li F P, Strong L C, Fraumeni Jr J F, Nelson C E, Kim D H, Kassel J, Gryka M A, Bischoff F Z, Tainsky M A. et al . Germ line p 53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.  Science. 1990;  250 1233-1238
• 15 National-Cancer-Institute .Third national cancer survey: incidence data. DHEW Publ. No. (NIH) 75 - 787. NCI monograph. edited. Bethesda; National Cancer Institute 1975: 1-41
• 16 Ribeiro R C, Sandrini F, Figueiredo B, Zambetti G P, Michalkiewicz E, Lafferty A R, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis C A, Sandrini R. An inherited p 53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma.  Proc Natl Acad Sci USA. 2001;  98 9330-9335
• 17 Saeger W, Fassnacht M, Chita R, Prager G, Nies C, Lorenz K, Barlehner E, Simon D, Niederle B, Beuschlein F, Allolio B, Reincke M. High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients.  Hum Pathol. 2003;  34 180-186
• 18 Sameshima Y, Tsunematsu Y, Watanabe S, Tsukamoto T, Kawa-ha K, Hirata Y, Mizoguchi H, Sugimura T, Terada M, Yokota J. Detection of novel germ-line p 53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma.  J Natl Cancer Inst. 1992;  84 703-707
• 19 Schteingart D E, Doherty P G, Gauger P G, Giordano T J, Hammer G D, Korobkin M, Worden F P. Management of patients with adrenal cancer - recommendations of an international consensus conference.  . 2005;  12 667-680 (Review)
• 20 Sredni S T, Zerbini M C, Latorre M R, Alves V A. p 53 as a prognostic factor in adrenocortical tumors of adults and children.  Braz J Med Biol Res. 2003;  36 23-27
• 21 Sullivan M, Boileau M, Hodges C V. Adrenal cortical carcinoma.  J Urol. 1978;  120 660-665
• 22 Wagner J, Portwine C, Rabin K, Leclerc J M, Narod S A, Malkin D. High frequency of germline p 53 mutations in childhood adrenocortical cancer.  J Natl Cancer Inst. 1994;  86 1707-1710
• 23 Wajchenberg B, Albergaria P M, Medonca B, Latronico A, Campos C P, Ferreira A V, Zerbini M, Liberman B, Carlos G G, Kirschner M. Adrenocortical carcinoma: clinical and laboratory observations.  Cancer. 2000;  88 711-736
• 24 Wooten M D, King D K. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature.  Cancer. 1993;  72 3145-3155

1 This work was supported by the Deutsche Krebshilfe (grant # 106080) to B. A. and the European Union (grant # MOIF-7394) to M. F.